Mary-Ann Fitzcharles

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2917718/publications.pdf

Version: 2024-02-01

81434 39744 10,428 111 41 98 citations h-index g-index papers 117 117 117 7924 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cautious Hope for Cannabidiol (<scp>CBD</scp>) in Rheumatology Care. Arthritis Care and Research, 2023, 75, 1371-1375.	1.5	22
2	Altered serum bile acid profile in fibromyalgia is associated with specific gut microbiome changes and symptom severity. Pain, 2023, 164, e66-e76.	2.0	9
3	Registerâ€based studies on cannabisâ€based medicines and medical cannabis need reliable diagnoses and cannabis treatment details. European Journal of Pain, 2022, 26, 3-4.	1.4	2
4	Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. CNS Drugs, 2022, 36, 31-44.	2.7	34
5	Dietary Intake Is Unlikely to Explain Symptom Severity and Syndrome-Specific Microbiome Alterations in a Cohort of Women with Fibromyalgia. International Journal of Environmental Research and Public Health, 2022, 19, 3254.	1.2	4
6	Longâ€term observational studies with cannabisâ€based medicines for chronic nonâ€cancer pain: A systematic review and metaâ€analysis of effectiveness and safety. European Journal of Pain, 2022, 26, 1221-1233.	1.4	23
7	Nociplastic pain is functional pain – Authors' reply. Lancet, The, 2022, 399, 1604.	6.3	1
8	Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain). Current Rheumatology Reports, 2022, 24, 238-246.	2.1	9
9	Is opioid therapy for chronic nonâ€cancer pain associated with a greater risk of allâ€cause mortality compared to nonâ€opioid analgesics? A systematic review of propensity score matched observational studies. European Journal of Pain, 2021, 25, 1195-1208.	1.4	10
10	The burden of waiting to access pain clinic services: perceptions and experiences of patients with rheumatic conditions. BMC Health Services Research, 2021, 21, 160.	0.9	12
11	Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet, The, 2021, 397, 2098-2110.	6.3	440
12	Fibromyalgia in Older Individuals. Drugs and Aging, 2021, 38, 735-749.	1.3	7
13	Cannabis-Based Medicines in Fibromyalgia. , 2021, , 255-266.		O
14	Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain. Drugs, 2021, 81, 2103-2116.	4.9	16
15	Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 115-119.	0.4	O
16	Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study. Clinical and Experimental Rheumatology, 2021, 39, 115-119.	0.4	10
17	Upregulation of cortical GABAA receptor concentration in fibromyalgia. Pain, 2020, 161, 74-82.	2.0	30
18	All-cause mortality in patients with long-term opioid therapy compared with non-opioid analgesics for chronic non-cancer pain: a database study. BMC Medicine, 2020, 18, 162.	2.3	24

#	Article	IF	CITATIONS
19	Considering the potential for an increase in chronic pain after the COVID-19 pandemic. Pain, 2020, 161, 1694-1697.	2.0	225
20	The association between waiting time and multidisciplinary pain treatment outcomes in patients with rheumatic conditions. BMC Rheumatology, 2020, 4, 59.	0.6	7
21	Ensuring access to safe, effective, and affordable cannabisâ€based medicines. British Journal of Clinical Pharmacology, 2020, 86, 630-634.	1.1	14
22	Opioids and Cannabinoids for Osteoarthritis: Either, Both, or Neither. Current Treatment Options in Rheumatology, 2020, 6, 29-44.	0.6	0
23	Medical Cannabis Use by Rheumatology Patients Following Recreational Legalization: A Prospective Observational Study of 1000 Patients in Canada. ACR Open Rheumatology, 2020, 2, 286-293.	0.9	22
24	Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic. Journal of Rheumatology, 2020, 47, 783-786.	1.0	19
25	Reply to Chaturvedi. Pain, 2020, 161, 2652-2653.	2.0	1
26	Gut microbiome: pertinence in fibromyalgia. Clinical and Experimental Rheumatology, 2020, 38 Suppl 123, 99-104.	0.4	5
27	Cannabis for rheumatic pain: hope or hype?. Clinical Rheumatology, 2019, 38, 2655-2657.	1.0	0
28	Cannabinoids in the treatment of rheumatic diseases: Pros and cons. Autoimmunity Reviews, 2019, 18, 102409.	2.5	26
29	Medical cannabis: strengthening evidence in the face of hype and public pressure. Cmaj, 2019, 191, E907-E908.	0.9	16
30	Factors associated with waiting times for persons with rheumatic conditions in multidisciplinary pain treatment facilities. Journal of Pain Research, 2019, Volume 12, 2379-2390.	0.8	9
31	Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases. Journal of Rheumatology, 2019, 46, 532-538.	1.0	38
32	Efficacy, tolerability and safety of cannabis-based medicines for cancer pain. Schmerz, 2019, 33, 424-436.	2.7	72
33	Response to Wolfe. Letter to the Editor, "Fibromyalgia Criteria― Journal of Pain, 2019, 20, 741-742.	0.7	2
34	Cannabis-Based Medicines and Medical Cannabis in Rheumatic Diseases: A Treasure Chest or Pandora's box. Current Treatment Options in Rheumatology, 2019, 5, 258-271.	0.6	1
35	Fibromyalgia as a chronic primary pain syndrome: issues to discuss. Pain, 2019, 160, 2651-2652.	2.0	12
36	Altered microbiome composition in individuals with fibromyalgia. Pain, 2019, 160, 2589-2602.	2.0	130

#	Article	IF	CITATIONS
37	AAPT Diagnostic Criteria for Fibromyalgia. Journal of Pain, 2019, 20, 611-628.	0.7	222
38	Medical Cannabis for Older Patients. Drugs and Aging, 2019, 36, 39-51.	1.3	69
39	Fibromyalgia syndrome: under-, over- and misdiagnosis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 116, 90-97.	0.4	25
40	Attitudes Toward and Management of Fibromyalgia. Journal of Clinical Rheumatology, 2018, 24, 243-249.	0.5	13
41	Postoperative Pain Management in Vitreoretinal Surgery for Retinal Detachment: A Systematic Review of Randomized Controlled Trials. Journal of Vitreoretinal Diseases, 2018, 2, 160-175.	0.2	1
42	Unravelling Fibromyalgiaâ€"Steps Toward Individualized Management. Journal of Pain, 2018, 19, 125-134.	0.7	50
43	Dr. Fitzcharles and Dr. Shir reply. Journal of Rheumatology, 2018, 45, 1071.2-1071.	1.0	0
44	Facts and myths pertaining to fibromyalgia. Dialogues in Clinical Neuroscience, 2018, 20, 53-62.	1.8	123
45	The Perils of Overestimating the Efficacy of Cannabis-Based Medicines for Chronic Pain Management. Pain Physician, 2018, 21, E79-E80.	0.3	5
46	Another Nasty Effect of Opioids: Attenuating the Benefits of Motivational Interviewing in Fibromyalgia?. Journal of Rheumatology, 2017, 44, 407-409.	1.0	3
47	Histological Underpinnings of Grey Matter Changes in Fibromyalgia Investigated Using Multimodal Brain Imaging. Journal of Neuroscience, 2017, 37, 1090-1101.	1.7	69
48	Opioids for RA: a clinical dilemma. Nature Reviews Rheumatology, 2017, 13, 521-522.	3.5	2
49	Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Reports, 2017, 2, e598.	1.4	51
50	Treatâ€toâ€Target Strategy for Fibromyalgia: Opening the Dialogue. Arthritis Care and Research, 2017, 69, 462-466.	1.5	13
51	Cannabinoids in Pain Management and Palliative Medicine. Deutsches Ärzteblatt International, 2017, 114, 627-634.	0.6	66
52	A paradigm change to inform fibromyalgia research priorities by engaging patients and health care professionals. Canadian Journal of Pain, 2017, 1, 137-147.	0.6	19
53	Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care and Research, 2016, 68, 681-688.	1.5	60
54	Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain, 2016, 157, 2792-2797.	2.0	39

#	Article	IF	CITATIONS
55	Pain Management for the Young Adult Rheumatology Patient in an Era of Medicinal Marijuana Legalization. Journal of Rheumatology, 2016, 43, 686-688.	1.0	2
56	2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism, 2016, 46, 319-329.	1.6	1,173
57	Cannabinoids for fibromyalgia. The Cochrane Library, 2016, 7, CD011694.	1.5	56
58	Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases. Current Rheumatology Reports, 2016, 18, 76.	2.1	22
59	Dr. Fitzcharles, <i>et al,</i> reply. Journal of Rheumatology, 2016, 43, 2077.2-2077.	1.0	O
60	Disability in Fibromyalgia Associates with Symptom Severity and Occupation Characteristics. Journal of Rheumatology, 2016, 43, 931-936.	1.0	23
61	Attitudes of Israeli Rheumatologists to the Use of Medical Cannabis as Therapy for Rheumatic Disorders. Rambam Maimonides Medical Journal, 2016, 7, e0012.	0.4	28
62	Fibromyalgia. Nature Reviews Disease Primers, 2015, 1, 15022.	18.1	308
63	Expanding Medical Marijuana Access in Canada: Considerations for the Rheumatologist. Journal of Rheumatology, 2015, 42, 143-145.	1.0	11
64	Pregabalin for chronic pain: does one medication fit all?. Current Medical Research and Opinion, 2015, 31, 1403-1411.	0.9	9
65	Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open, 2015, 1, e000146.	1.8	64
66	Multidisciplinary treatment for rheumatic pain. Best Practice and Research in Clinical Rheumatology, 2015, 29, 156-163.	1.4	9
67	Adjudication of Fibromyalgia Syndrome: Challenges in the Medicolegal Arena. Pain Research and Management, 2014, 19, 287-292.	0.7	5
68	The Association of Socioeconomic Status and Symptom Severity in Persons with Fibromyalgia. Journal of Rheumatology, 2014, 41, 1398-1404.	1.0	44
69	The Dilemma of Medical Marijuana Use by Rheumatology Patients. Arthritis Care and Research, 2014, 66, 797-801.	1.5	23
70	Management of Fibromyalgia in Older Adults. Drugs and Aging, 2014, 31, 711-719.	1.3	7
71	Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Research and Therapy, 2014, 16, 201.	1.6	126
72	Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints. BMC Musculoskeletal Disorders, 2014, 15, 258.	0.8	48

#	Article	IF	CITATIONS
73	Medical cannabis: what advice should we be giving our rheumatology patients?. International Journal of Clinical Rheumatology, 2014, 9, 341-344.	0.3	O
74	Canadian Pain Society and Canadian Rheumatology Association Recommendations for Rational Care of Persons with Fibromyalgia. A Summary Report. Journal of Rheumatology, 2013, 40, 1388-1393.	1.0	43
75	Classification and Clinical Diagnosis of Fibromyalgia Syndrome: Recommendations of Recent Evidence-Based Interdisciplinary Guidelines. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-9.	0.5	49
76	Treatment of Fibromyalgia Syndrome: Recommendations of Recent Evidence-Based Interdisciplinary Guidelines with Special Emphasis on Complementary and Alternative Therapies. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-7.	0.5	108
77	A Medicolegal Analysis of Worker Appeals for Fibromyalgia as a Compensable Condition Following Workplace Soft-tissue Injury. Journal of Rheumatology, 2013, 40, 323-328.	1.0	10
78	Fibromyalgia: evolving concepts over the past 2 decades. Cmaj, 2013, 185, E645-E651.	0.9	29
79	Dr. Fitzcharles, <i>et al</i> reply. Journal of Rheumatology, 2013, 40, 1622-1622.	1.0	0
80	Opioid Use in Fibromyalgia Is Associated with Negative Health Related Measures in a Prospective Cohort Study. Pain Research and Treatment, 2013, 2013, 1-7.	1.7	46
81	2012 Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome: Executive Summary. Pain Research and Management, 2013, 18, 119-126.	0.7	299
82	The Clinical Concept of Fibromyalgia as a Changing Paradigm in the Past 20 Years. Pain Research and Treatment, 2012, 2012, 1-8.	1.7	50
83	The 2010 American college of rheumatology fibromyalgia survey diagnostic criteria and symptom severity scale is a valid and reliable tool in a French speaking fibromyalgia cohort. BMC Musculoskeletal Disorders, 2012, 13, 179.	0.8	43
84	Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care and Research, 2012, 64, 1202-1208.	1.5	27
85	Clinical implications for cannabinoid use in the rheumatic diseases: Potential for help or harm?. Arthritis and Rheumatism, 2012, 64, 2417-2425.	6.7	14
86	Opioid Use, Misuse, and Abuse in Patients Labeled as Fibromyalgia. American Journal of Medicine, 2011, 124, 955-960.	0.6	91
87	New Concepts in Pain Research and Pain Management of the Rheumatic Diseases. Seminars in Arthritis and Rheumatism, 2011, 41, 319-334.	1.6	48
88	Imaging studies in Freund's complete adjuvant model of regional polyarthritis, a model suitable for the study of pain mechanisms, in the rat. Arthritis and Rheumatism, 2011, 63, 1573-1581.	6.7	48
89	Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology, 2011, 38, 1113-1122.	1.0	1,162
90	The Longitudinal Outcome of Fibromyalgia: A Study of 1555 Patients. Journal of Rheumatology, 2011, 38, 2238-2246.	1.0	130

#	Article	IF	CITATIONS
91	Management of Chronic Pain in the Rheumatic Diseases with Insights for the Clinician. Therapeutic Advances in Musculoskeletal Disease, 2011, 3, 179-190.	1.2	26
92	The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial. Anesthesia and Analgesia, 2010, 110, 604-610.	1.1	225
93	The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care and Research, 2010, 62, 600-610.	1.5	2,964
94	Management of Chronic Arthritis Pain in the Elderly. Drugs and Aging, 2010, 27, 471-490.	1.3	69
95	Opioid guidelines: helpful for the rheumatologist?. Nature Reviews Rheumatology, 2009, 5, 242-244.	3. 5	4
96	Should Rheumatologists Retain Ownership of Fibromyalgia?. Journal of Rheumatology, 2009, 36, 667-670.	1.0	36
97	Patient Barriers to Pain Management May Contribute to Poor Pain Control in Rheumatoid Arthritis. Journal of Pain, 2009, 10, 300-305.	0.7	36
98	New Concepts in Rheumatic Pain. Rheumatic Disease Clinics of North America, 2008, 34, 267-283.	0.8	19
99	Preface. Rheumatic Disease Clinics of North America, 2008, 34, xi-xii.	0.8	0
100	Pain: Understanding and challenges for the rheumatologist. Arthritis and Rheumatism, 2005, 52, 3685-3692.	6.7	45
101	Clinical profile of rheumatic disease patients referred to a multidisciplinary pain center. Journal of Rheumatology, 2004, 31, 359-63.	1.0	6
102	A study of standard care in fibromyalgia syndrome: a favorable outcome. Journal of Rheumatology, 2003, 30, 154-9.	1.0	38
103	Cannabis for Chronic Pain: Case Series and Implications for Clinicians. Pain Research and Management, 2002, 7, 95-99.	0.7	33
104	The use of infliximab in academic rheumatology practice: an audit of early clinical experience. Journal of Rheumatology, 2002, 29, 2525-30.	1.0	28
105	Pain and pain relief in fibromyalgia patients followed for three years. Arthritis and Rheumatism, 2001, 45, 355-361.	6.7	44
106	The needs of patients with arthritis: The patient's perspective. Arthritis and Rheumatism, 1999, 12, 85-95.	6.7	67
107	The Overdiagnosis of Fibromyalgia Syndrome. American Journal of Medicine, 1997, 103, 44-50.	0.6	76
108	Alternative medicine use in fibromyalgia syndrome. Arthritis and Rheumatism, 1996, 9, 13-17.	6.7	144

#	Article	IF	CITATIONS
109	Sexual and physical abuse in women with fibromyalgia syndrome. Arthritis and Rheumatism, 1995, 38, 235-241.	6.7	199
110	Reactive fibromyalgia syndrome. Arthritis and Rheumatism, 1992, 35, 678-681.	6.7	128
111	Concerns about the taxonomy, definition and coding of fibromyalgia syndrome in ICD-11: the potential for negative consequences for patient care and research. Clinical and Experimental Rheumatology, 0, ,	0.4	0